Lakhmir Chawla
Direktor/Vorstandsmitglied bei REVELATION BIOSCIENCES, INC.
Profil
Lakhmir S.
Chawla is currently a Director at ExThera Medical Corp.
and an Independent Director at Revelation Biosciences, Inc. He was previously an Independent Director at CalciMedica, Inc. (US), Chief Medical Officer at La Jolla Pharmaceutical Co., Professor at George Washington University, and Chief-Intensive Care Medicine Division at VA Medical Center (District of Columbia).
He received his undergraduate degree from Boston University and his doctorate from New Jersey Medical School in 1995.
Aktive Positionen von Lakhmir Chawla
| Unternehmen | Position | Beginn |
|---|---|---|
| REVELATION BIOSCIENCES, INC. | Direktor/Vorstandsmitglied | 27.09.2023 |
ExThera Medical Corp.
 ExThera Medical Corp. Medical/Nursing ServicesHealth Services ExThera Medical Corp. develops medical devices that address unmet clinical needs in the treatment of bloodstream infections and pathogen-reduction in blood banking. The company develops Seraph Microbind Affinity Blood Filter (Seraph), which captures and removes normal and drug-resistant bacteria, viruses, toxins, and pro-inflammatory cytokines from human blood; and offers solution for use in a dialysis, such as extracorporeal circuit for treating existing bloodstream infections. The company was founded in 2007 and is headquartered in Martinez, CA. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Lakhmir Chawla
| Unternehmen | Position | Ende |
|---|---|---|
CalciMedica, Inc. (US)
 CalciMedica, Inc. (US) BiotechnologyHealth Technology CalciMedica, Inc. is a holding company, which engages in drug development. It discovers and develops novel small molecule drugs for the treatment of inflammatory and autoimmune disorders and organ transplant rejection. The company was founded by Gonul Velicelebi, Kenneth Stauderman, Anjana Rao, Patrick Hogan, Stefan Feske, Michael Harpold, Tom Reed, and Jack Roos in December 2006 and is headquartered in La Jolla, CA. | Direktor/Vorstandsmitglied | 01.03.2023 |
| LA JOLLA PHARMACEUTICAL COMPANY | Technik-/Wissenschafts-/F&E-Leiter | 02.10.2020 |
| VA Medical Center (District of Columbia) | Corporate Officer/Principal | 01.01.2015 |
| George Washington University | Corporate Officer/Principal | 01.01.2014 |
Ausbildung von Lakhmir Chawla
| Boston University | Undergraduate Degree |
| New Jersey Medical School | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| REVELATION BIOSCIENCES, INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
La Jolla Pharmaceutical Co.
 La Jolla Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology La Jolla Pharmaceutical Co. operates as a biopharmaceutical company. It engages in the discovery, development and commercialization of therapies intended to improve outcomes in patients suffering from life-threatening diseases. Its products portfolio include GIAPREZA and XERAVA. The company was founded in 1989 and is headquartered in San Diego, CA. | Health Technology |
CalciMedica, Inc. (US)
CalciMedica, Inc. (US) BiotechnologyHealth Technology CalciMedica, Inc. is a holding company, which engages in drug development. It discovers and develops novel small molecule drugs for the treatment of inflammatory and autoimmune disorders and organ transplant rejection. The company was founded by Gonul Velicelebi, Kenneth Stauderman, Anjana Rao, Patrick Hogan, Stefan Feske, Michael Harpold, Tom Reed, and Jack Roos in December 2006 and is headquartered in La Jolla, CA. | Health Technology |
| VA Medical Center (District of Columbia) | Government |
ExThera Medical Corp.
ExThera Medical Corp. Medical/Nursing ServicesHealth Services ExThera Medical Corp. develops medical devices that address unmet clinical needs in the treatment of bloodstream infections and pathogen-reduction in blood banking. The company develops Seraph Microbind Affinity Blood Filter (Seraph), which captures and removes normal and drug-resistant bacteria, viruses, toxins, and pro-inflammatory cytokines from human blood; and offers solution for use in a dialysis, such as extracorporeal circuit for treating existing bloodstream infections. The company was founded in 2007 and is headquartered in Martinez, CA. | Health Services |